'Immunotherapies drives market growth' diaporamas de présentation

The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 8.5%, says business intelligence provider GBI Research. Browse complete Table of content here: https://marketreportscenter.com/reports/non-small-cell-lung-cancer-therapeutics-in-major-developed-markets-to-2021-emergence-of-immunotherapies-drives-market-growth-and-creates-a-competitive-second-line/

241 views • 7 slides

Non-Small Cell Lung Cancer Therapeutics Market Analysis to 2021

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

207 views • 5 slides

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021

142 views • 4 slides